Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review
Abstract Pulmonary arterial hypertension‐targeted therapies in portopulmonary hypertension (PoPH) are scarce, let alone for patients with chronic liver failure (CLF) and hepatopulmonary syndrome (HPS). A 48‐year male was admitted to the hospital because of cirrhosis for 18 years, systemic oedema, an...
Main Authors: | Niuniu Li, Qiang Wu, Juan Meng, Cheng Feng, Siwei Jiang, Meixia Chen, Wenhui Xu, Fei Wang, Yifan Zhang, Juncai Liu, Cheng Xu, Gaolin Liu, Hong Gao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.14431 |
Similar Items
-
Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview
by: Jose T. Altamirano, et al.
Published: (2012-09-01) -
Long term survival of a biliary atresia patient by repeated liver transplantations for portopulmonary hypertension in addition to the hepatopulmonary syndrome
by: Shintaro Hayashida, et al.
Published: (2023-02-01) -
Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies
by: Nick H. Kim, et al.
Published: (2024-01-01) -
Differential diagnosis of hepatopulmonary syndrome (HPS): Portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT)
by: Inna Krynytska, et al.
Published: (2017-11-01) -
Hepatopulmonary syndrome and portopulmonary hypertension
by: R Naeije
Published: (2003-03-01)